RECIST 1.1—Update and clarification: From the RECIST committee Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present


Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Monday, May 30, 2016

RECIST 1.1—Update and clarification: From the RECIST committee

Update and clarification:
 May 14, 2016


Clarification on how to select target lesions and what to do with measurable lesions which are not selected for target disease response assessment.
Clarification on the definition of stable disease.
Clarification on the role of Fluorodeoxy-glucose (18F) (FDG)-positron emission tomography (PET)/PET-computed tomography in the context of RECIST 1.1.

The Response Evaluation Criteria in Solid Tumours (RECIST) were developed and published in 2000, based on the original World Health Organisation guidelines first published in 1981. In 2009, revisions were made (RECIST 1.1) incorporating major changes, including a reduction in the number of lesions to be assessed, a new measurement method to classify lymph nodes as pathologic or normal, the clarification of the requirement to confirm a complete response or partial response and new methodologies for more appropriate measurement of disease progression. The purpose of this paper was to summarise the questions posed and the clarifications provided as an update to the 2009 publication.


Post a Comment

Your comments?